Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

A GFP Retinal Prion Proteins Intracellular Trafficking via Endocytic Intermediates

Tarunkanti Mondal

The prion protein (PrP) is a key molecule implicated in neurodegenerative disorders. Understanding its intracellular trafficking is essential for unraveling its physiological and pathological functions. This article focuses on the intracellular trafficking of a green fluorescent protein (GFP) tagged PrP in retinal cells, specifically exploring its transport via endocytic intermediates. Endocytic pathways, including clathrin-mediated endocytosis, caveolaemediated endocytosis, and macropinocytosis, play a crucial role in PrP internalization and trafficking. Endocytic intermediates, such as early endosomes, late endosomes, and lysosomes, are involved in sorting, recycling, and degradation of endocytosed proteins. Live-cell imaging and colocalization studies have provided insights into GFPPrP’s movement and localization within these organelles. Studies reveal rapid internalization of PrP via clathrinmediated endocytosis, with subsequent transport to early endosomes. A fraction of PrP is recycled, while the remainder progresses to late endosomes and lysosomes for degradation. Elucidating the intracellular trafficking of GFP-PrP and its association with endocytic intermediates enhances our understanding of PrP’s functions and implications in neurodegenerative diseases. Further investigations are needed to explore the molecular machinery involved and the impact of disease-associated mutations. This knowledge may contribute to potential therapeutic strategies for prion diseases.